• Lantheus will present Alzheimer's imaging data at the Clinical Trials on Alzheimer's Disease meeting in Boston, Nov. 16-19, 2026.
• Presentations scheduled for Nov. 16-17 include pivotal Phase 3 studies evaluating florquinitau F 18 PET's ability to detect early Alzheimer's tau pathology.
• A separate study reports minimal age dependence of astrocytic MAO-B across the Alzheimer's disease spectrum using 18F-FDED PET imaging.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lantheus Holdings Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611020830PRIMZONEFULLFEED9867670) on November 02, 2026, and is solely responsible for the information contained therein.